1e
19
1
49
2
2
18
1b
1d
18
3d
3c
1d
2 29
1d
25
Mark A Oyama, DVM, MSCE, DACVIM
78
3c
Professor of Cardiology
28
af
3
61
Professor, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine
a4
Charlotte Newton Sheppard Endowed Chair of Medicine, University of Pennsylvania School of Veterinary Medicine
ab
Chair, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine
b5
Associate Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
11
Department: Cardiology
4
1
b
1d
46
Contact information
59
4
3
3
1d
59
Department of Clinical Studies-Philadelphia
42 Ryan Veterinary Hospital of the University of Pennsylvania
25 School of Veterinary Medicine
22 University of Pennsylvania
32 3900 Spruce St.
Philadelphia, PA 19104
26
42 Ryan Veterinary Hospital of the University of Pennsylvania
25 School of Veterinary Medicine
22 University of Pennsylvania
32 3900 Spruce St.
Philadelphia, PA 19104
2e
Office: 215-898-3331
30
f
30
18
Publications
23 a
3
2
29
23 a
Links
a7 Search PubMed for articles
d
4
b
1f
a7 Search PubMed for articles
d
13
Education:
21 8 DVM 27 (Doctor Veterinary Medicine) c
2f University of Illinois, 1994.
21 9 MSCE 38 (Masters of Science in Clinical Epidemiology) c
33 University of Pennslyvania, 2015.
c
3
3
3
3
8d
Permanent link21 8 DVM 27 (Doctor Veterinary Medicine) c
2f University of Illinois, 1994.
21 9 MSCE 38 (Masters of Science in Clinical Epidemiology) c
33 University of Pennslyvania, 2015.
c
2 29
21
1e
1d
24
5e
1b Diuretic resistance
17 Clinical trials
38 Serotonin signaling and myxomatous valve disease
38 Animal models of heart disease and heart failure
25 Epidemiology and biostatistics
65
3f Molecular mechanisms of myxomatous mitral valve disease
1b Diuretic resistance
25 Epidemiology and biostatistics
1a 29
27
Description of Research Expertise
4f Cardiac biomarkers (troponin, natriuretic peptides [BNP, ANP])1b Diuretic resistance
17 Clinical trials
38 Serotonin signaling and myxomatous valve disease
38 Animal models of heart disease and heart failure
25 Epidemiology and biostatistics
65
Description of Clinical Expertise
3a Canine and feline models of heart disease3f Molecular mechanisms of myxomatous mitral valve disease
1b Diuretic resistance
25 Epidemiology and biostatistics
1a 29
23
1ee Castillero E, Fitzpatrick E, Keeney SJ, D'Angelo AM, Pressly BB, Simpson MT, Kurade M, Erwin WC, Moreno V, Camillo C, Shukla HJ, Inamdar VV, Aghali A, Grau JB, Salvati E, Nissim I, Rauova L, Oyama MA, Stachelek SJ, Brown C, Krieger AM, Levy RJ, Ferrari G.: Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation. Sci Transl Med 15: eadc9606, Jan 2023.
161 Pedro B, Mavropoulou A, Oyama MA, Linney C, Neves J, Dukes-McEwan J, Fontes-Sousa AP, Gelzer AR.: Optimal rate control in dogs with atrial fibrillation-ORCA study-Multicenter prospective observational study: Prognostic impact and predictors of rate control. J Vet Intern Med 2023.
c6 Oyama MA, Adin D.: Toward quantification of loop diuretic responsiveness for congestive heart failure. J Vet Intern Med 2023.
147 Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.: Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease. J Am Heart Assoc 10: e018923, May 2021.
12b Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.: Gut Dysbiosis and Its Associations with Gut Microbiota-Derived Metabolites in Dogs with Myxomatous Mitral Valve Disease. mSystems 6: e00111-21, Apr 2021.
e5 Crooks AV, Gelzer AR, Oyama MA, Kraus MS.: Quiet timer blanking in a dog with sick sinus syndrome and a permanent transvenous pacemaker. J Vet Cardiol 2021.
198 Wilshaw J, Rosenthal SL, Wess G, Dickson D, Bevilacqua L, Dutton E, Deinert M, Abrantes R, Schneider I, Oyama MA, Gordon SG, Elliott J, Xia D, Boswood A.: Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. J Vet Intern Med 2021.
133 Oyama MA, Gelzer AR, Kraus MS.: Letter regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial" J Vet Intern Med 2021.
134 Larouche-Lebel É, Loughran KA, Huh T, Oyama MA.: Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. J Vet Intern Med 2021.
2c
7
1d
1f
Selected Publications
13a Tinsley AT, Oyama MA, Reineke EL.: Animal Trauma Triage Score, Modified Glasgow Coma Scale, age, and weight were associated with outcome in feline bite wounds (1,065 cases): a VetCOT registry study. J Am Vet Med Assoc 261: 881-887, Mar 2023.1ee Castillero E, Fitzpatrick E, Keeney SJ, D'Angelo AM, Pressly BB, Simpson MT, Kurade M, Erwin WC, Moreno V, Camillo C, Shukla HJ, Inamdar VV, Aghali A, Grau JB, Salvati E, Nissim I, Rauova L, Oyama MA, Stachelek SJ, Brown C, Krieger AM, Levy RJ, Ferrari G.: Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation. Sci Transl Med 15: eadc9606, Jan 2023.
161 Pedro B, Mavropoulou A, Oyama MA, Linney C, Neves J, Dukes-McEwan J, Fontes-Sousa AP, Gelzer AR.: Optimal rate control in dogs with atrial fibrillation-ORCA study-Multicenter prospective observational study: Prognostic impact and predictors of rate control. J Vet Intern Med 2023.
c6 Oyama MA, Adin D.: Toward quantification of loop diuretic responsiveness for congestive heart failure. J Vet Intern Med 2023.
147 Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.: Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease. J Am Heart Assoc 10: e018923, May 2021.
12b Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.: Gut Dysbiosis and Its Associations with Gut Microbiota-Derived Metabolites in Dogs with Myxomatous Mitral Valve Disease. mSystems 6: e00111-21, Apr 2021.
e5 Crooks AV, Gelzer AR, Oyama MA, Kraus MS.: Quiet timer blanking in a dog with sick sinus syndrome and a permanent transvenous pacemaker. J Vet Cardiol 2021.
198 Wilshaw J, Rosenthal SL, Wess G, Dickson D, Bevilacqua L, Dutton E, Deinert M, Abrantes R, Schneider I, Oyama MA, Gordon SG, Elliott J, Xia D, Boswood A.: Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. J Vet Intern Med 2021.
133 Oyama MA, Gelzer AR, Kraus MS.: Letter regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial" J Vet Intern Med 2021.
134 Larouche-Lebel É, Loughran KA, Huh T, Oyama MA.: Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. J Vet Intern Med 2021.
2c